Search Results for

S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Continue Reading »

---

Search Again

• All Trial Categories Amyloidosis  (1) Anal  (1) Bladder/Urinary Tract Cancer  (5)    Adjuvant  (1)    Metastatic  (2) Brain  (9)    Glioblastoma Multiforme (GBM)  (1)    Other Brain Tumors  (3) Breast  (14)    Breast Cancer Adjuvant  (1)    Breast Cancer Neoadjuvant  (2) Cancer Control/Symptom Management  (20) Carcinoid Tumors  (2) Colorectal Cancer  (6)    Metastatic  (1)    Rectal Neoadjuvant  (1) Esophageal Cancer  (4) Gastric Cancer  (3) Head/Neck Cancer  (9) Leukemia  (2) Lung Cancer  (18)    Non-Small Cell Lung Cancer  (14)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (2)       Adjuvant Treatment for Resected NSCLC  (2)    Small Cell Lung Cancer  (3)       Extensive Stage SCLC  (1) MATCH Trial  (3) Melanoma  (2) Merkel Cell Carcinoma  (1) Misc. Gynecology  (4) Multiple Myeloma  (2) Ovarian  (2) Pancreatic  (8)    Metastatic Disease  (1) Prostate  (9) Renal Cell/Kidney Cancer  (3)    Locally Advanced/Metastatic  (1) Sarcoma  (1)